Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term Outcomes of Low-Energy Open Tibial Shaft Fractures: A 10-Year Follow-up Study of Infection Rates.

West African journal of medicine·2026
Same author

INTIMATE PARTNER VIOLENCE AMONG WOMEN WITH GYNAECOLOGIC HEALTH CHALLENGES AT THE UNIVERSITY COLLEGE HOSPITAL, IBADAN, NIGERIA: A CROSS-SECTIONAL STUDY.

Annals of Ibadan postgraduate medicine·2026
Same author

A Two-Year Prospective Study of the Mechanisms and Patterns of Limb Injury in Multiply Injured Patients at UNIOSUN Teaching Hospital, Osogbo, Nigeria.

West African journal of medicine·2025
Same author

Knowledge, Attitude and Perception of Medical Students at the University College Hospital, Ibadan towards Female Genital Mutilation.

West African journal of medicine·2025
Same author

Evaluation of Patients' Satisfaction with Healthcare Services Provided at the National Health Insurance Authority Clinic of a Tertiary Hospital in South-West, Nigeria.

West African journal of medicine·2025
Same author

Intramural Pregnancy: An Intriguing Diagnosis in a Resource Constraint Practice.

West African journal of medicine·2024

Related Experiment Video

Updated: May 1, 2026

Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri
05:21

Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri

Published on: September 12, 2025

833

Sublingual misoprostol to decrease blood loss after caesarean delivery: a randomised controlled trial.

I A Ugwu1, O O Enabor, A B Adeyemi

  • 1Department of Obstetrics and Gynaecology, University College Hospital , Ibadan , Nigeria.

Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology
|April 15, 2014
PubMed
Summary

Adding sublingual misoprostol to intravenous oxytocin significantly reduces postpartum blood loss and the need for additional uterotonics during caesarean sections. However, this combination increases the risk of shivering and fever.

Keywords:
Caesarean sectionmisoprostolpostpartum haemorrhagesub-Saharan Africa

More Related Videos

Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse
03:43

Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse

Published on: September 13, 2022

8.9K
An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP
14:56

An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP

Published on: January 27, 2010

22.5K

Related Experiment Videos

Last Updated: May 1, 2026

Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri
05:21

Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri

Published on: September 12, 2025

833
Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse
03:43

Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse

Published on: September 13, 2022

8.9K
An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP
14:56

An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP

Published on: January 27, 2010

22.5K

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Surgical Safety

Background:

  • Postpartum hemorrhage remains a leading cause of maternal mortality globally.
  • Oxytocin is the standard uterotonic for preventing postpartum hemorrhage after caesarean delivery.
  • Alternative or adjunct therapies are being investigated to improve efficacy and reduce blood loss.

Purpose of the Study:

  • To compare the efficacy of sublingual misoprostol plus intravenous oxytocin versus oxytocin alone in reducing blood loss during and after caesarean sections.
  • To evaluate the need for additional uterotonics and assess the side-effect profile of the combined regimen.

Main Methods:

  • A randomized controlled trial involving 120 women undergoing caesarean delivery.
  • Group A received intravenous oxytocin alone; Group B received sublingual misoprostol and intravenous oxytocin.
  • Outcome measures included blood loss, need for additional uterotonics, packed cell volume changes, and side effects.

Main Results:

  • Group B demonstrated significantly lower intraoperative (451.3 ml vs 551.2 ml) and postoperative (22.7 ml vs 42.2 ml) blood loss compared to Group A.
  • The need for additional uterotonics was significantly lower in Group B (27.6% vs 66.7%).
  • Group B experienced a higher incidence of shivering (7.4 times) and fever (9.0 times).

Conclusions:

  • The addition of sublingual misoprostol to intravenous oxytocin is effective in reducing postpartum blood loss and the requirement for additional uterotonics following caesarean section.
  • This combination therapy is associated with an increased risk of adverse events, specifically shivering and fever.